LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Automated Extraction System Produces High Quality RNA-free DNA

By LabMedica International staff writers
Posted on 18 Oct 2015
FlexSTAR+ completely automates the DNA extraction process
FlexSTAR+ completely automates the DNA extraction process (Photo courtesy of AutoGen)
A state-of-the-art precipitation-based system completely automates the DNA extraction process from primary tube sampling to final DNA elution into storage tubes.

The AutoGen (Holliston, MA, USA), FlexSTAR+ platform is a system that produces RNA-free DNA in an extremely user-friendly environment.

The FlexSTAR+ system includes protocols for fresh or frozen blood samples of 1 to 2 milliliters, 3 to 5 milliliters, and 6 to 10 milliliters. The instrument can draw samples from a variety of primary tube sizes, running up to 30 samples in a batch. It reads and records barcodes on primary tubes, has an internal barcode scanner to verify sample input and DNA output positions, provides liquid level detection for accurate pipetting, and delivers its final elution in SBS (sterile barrier system)-type storage tubes of the user’s choosing.

FlexSTAR+ features sample tracking and reporting software that verifies work lists from LIM (laboratory information management) input, creates a map of sample and DNA positions, tracks samples through the extraction process, and sends final reports back to LIMs. The software also sends an email or text alert to notify the operator when the run is complete.

The extraction process operates with Qiagen (Venlo, The Netherlands) FlexiGene chemistry. This precipitation-based procedure yields cleaner, longer-stranded DNA than does magnetic bead-based methods. Furthermore, since the Qiagen DNA extraction process begins with the collection of the white cell nuclei pellet, it eliminates RNA contamination that can occur with magnetic bead technology and other technologies that produce total nucleic acid instead of pure genomic DNA.

“Biorepositories, genetic treatment and cancer centers, and specialty diagnostic labs that currently are using Qiagen’s AutoPure solution for DNA extraction will be familiar and comfortable with precipitation technology,” said Bob Sullivan, president and CEO of AutoGen. “FlexSTAR+ is a logical step-up for them. In fact, it is a superior solution for any lab that wants to generate higher quality, higher yield genomic DNA with less work and errors and far less likelihood of RNA contamination, and that stands to benefit from the superior service for which AutoGen is known.”

Related Links:

AutoGen
Qiagen


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more